The antioxidant peptide SS-31 reversed persistent cerebrovascular oxidative stress caused by the combination of mild traumatic brain injury and hypertension in rats.
Complete reversal of oxidative stress with SS-31Daily SS-31 treatment normalized both cytoplasmic and mitochondrial superoxide production in brain arteries that were persistently elevated due to the combination of mild TBI and hypertension.
What the researchers found
In spontaneously hypertensive rats (SHRs), mild TBI induced significant long-term increases in both cytoplasmic and mitochondrial superoxide production in middle cerebral arteries at 2 weeks post-injury — an effect not seen in normotensive rats. Expression of the NADPH oxidase subunit Nox4 was also increased. Daily treatment with the mitochondria-targeted peptide SS-31 (5.7 mg/kg/day, i.p.) reversed all these oxidative stress markers to normal levels. NADPH oxidase inhibition (apocynin) also reduced the persistent oxidative stress, confirming the mechanistic pathway.
Why it matters
Millions of people experience mild concussions each year, and hypertension is extremely common — especially in older populations prone to falls. This study reveals that this common comorbidity combination may cause persistent brain blood vessel damage that wouldn't occur with either condition alone. The finding that SS-31 (a peptide already in clinical development for other conditions) can reverse this damage identifies a potential therapeutic approach.
How the study worked
Researchers induced mild traumatic brain injury in both normotensive Wistar rats and spontaneously hypertensive rats (SHRs). Two weeks after injury, middle cerebral arteries were isolated and assessed for cytoplasmic superoxide (using DHE staining) and mitochondrial superoxide (using MitoSox) by confocal microscopy. Nox4 expression was measured. SS-31 was administered daily at 5.7 mg/kg intraperitoneally. NADPH oxidase inhibition with apocynin was used to confirm the oxidative stress pathway.
What this study cannot tell us
This is an animal study using an inbred hypertensive rat strain, which may not perfectly model human essential hypertension. The study assessed cerebrovascular oxidative stress markers but did not measure functional outcomes like blood flow or cognition. The 2-week time point is relatively short, and it's unclear if the damage would eventually resolve without treatment or progress further. Only one dose of SS-31 was tested.
How to read the evidence
This is a preclinical animal study using a well-characterized rat model. The mechanistic approach is rigorous, with multiple measures of oxidative stress and pharmacological confirmation of the pathway. However, findings are limited to surrogate markers in an animal model without functional outcome data.
When this study was published
Published in 2019, this study contributes to the growing body of evidence supporting SS-31/elamipretide for mitochondrial protection across various conditions. The peptide continues to be investigated in clinical trials.
The bigger picture
SS-31 (elamipretide) is one of the most studied mitochondria-targeted peptides, already in clinical trials for heart failure and mitochondrial diseases. This study expands its potential applications to neurovascular protection after brain injury. The broader concept — that common comorbidities like hypertension can transform a transient injury response into persistent pathology — has important implications for how we manage concussion patients with pre-existing conditions.
Questions still open
- Does the persistent cerebrovascular oxidative stress in hypertensive rats after mild TBI lead to measurable cognitive decline?
- Would SS-31 treatment also restore cerebral blood flow autoregulation in this comorbidity model?
- Should concussion management protocols account for hypertension as a risk factor for prolonged vascular damage?
Common questions
What is SS-31 and how does it protect the brain?
Why does high blood pressure make concussions worse?
Read the original research
Hypertension Exacerbates Cerebrovascular Oxidative Stress Induced by Mild Traumatic Brain Injury: Protective Effects of the Mitochondria-Targeted Antioxidative Peptide SS-31.
Journal of neurotrauma, 36(23), 3309-3315
Citation
Czigler, Andras; Toth, Luca; Szarka, Nikolett; Berta, Gergely; Amrein, Kriszitina; Czeiter, Endre; Lendvai-Emmert, Dominika; Bodo, Kornelia; Tarantini, Stefano; Koller, Akos; Ungvari, Zoltan; Buki, Andras; Toth, Peter. (2019). Hypertension Exacerbates Cerebrovascular Oxidative Stress Induced by Mild Traumatic Brain Injury: Protective Effects of the Mitochondria-Targeted Antioxidative Peptide SS-31.. Journal of neurotrauma, 36(23), 3309-3315. https://doi.org/10.1089/neu.2019.6439